Class / Patent application number | Description | Number of patent applications / Date published |
424100770 | Phosphorus-containing organic compound | 37 |
20080267868 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex - A process for diagnostic imaging of heart or adrenal glands of a human being comprises administering to the human being a radiopharmaceutical containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound and a bidentate ligand and represented by the formula (1): [ | 10-30-2008 |
20080267869 | RADIOACTIVE TRANSITION METAL-IMIDO HETERO-DIPHOSPHINE COMPLEXES, THEIR PREPARATION AND RADIOPHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides radioactive metal heterocomplexes of formula (I): [(Me=N—R)L | 10-30-2008 |
20080279773 | SKELETAL-TARGETED RADIATION TO TREAT BONE-ASSOCIATED PATHOLOGIES - The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid. | 11-13-2008 |
20090060837 | COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS - The invention provides cobalamin compounds linked to a neutron capture therapy target (e.g. Boron-10 or Gadolinium-157), and optionally linked to a detectable moiety, as well as pharmaceutical compositions comprising the compounds, and methods for using the compounds in medical diagnosis and therapy. | 03-05-2009 |
20090117041 | Radiologic Agents for Monitoring Alzheimer's Disease Progression and Evaluating a Response to Therapy and Processes for the Preparation of Such Agents - Disclosed are certain cycloSalingenyl pyrimidine nucleoside monophosphates comprising positron emitters or gamma-emitting radiohalides, uses thereof for monitoring Alzheimer's disease progression and evaluating response to therapy and process for their preparation. | 05-07-2009 |
20090238759 | Method of Rapid Methylation of Alkene Compound and Kit for PET Tracer Preparation Using the Same - To provide a method of rapid methylation of alkenes, which is applicable to the preparation of a PET tracer and which enables alkenes to be methylated through cross coupling between SP | 09-24-2009 |
20090311178 | PYRROLINIDIUM DERIVATIVES AS M3 MUSCARINIC RECEPTORS - Compounds of formula (I) in salt or zwitterionic form, wherein R | 12-17-2009 |
20100092386 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI - The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same. | 04-15-2010 |
20100098632 | HYDROXYAPATITE PARTICLES - This document provides methods and materials related to hydroxyapatite particles. For example, hydroxyapatite particles, methods for making hydroxyapatite particles, and methods for using hydroxyapatite particles are provided herein. | 04-22-2010 |
20100202965 | ANNULUS FIBROSUS DETECTION IN INTERVERTEBRAL DISCS USING MOLECULAR IMAGING AGENTS - The present invention relates to methods for imaging annulus fibrosus tissue and a quantitative measurement of its local concentration in a sample using an agent comprising the compound of Formula I, a | 08-12-2010 |
20100215578 | Catalytic Radiofluorination - One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to piperazine compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the piperazine compounds contain a quaternary amine. Another aspect of the invention relates to arylphosphonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the phosphonium compound is a tetraaryl phosphonium salt. Another aspect of the present invention relates to a method of obtaining a positron emission image of a mammal, comprising the steps of administering to a mammal a compound of the invention, and acquiring a positron emission spectrum of the mammal. | 08-26-2010 |
20100221180 | IN VIVO IMAGING OF MYELINATION - A molecular probe for labeling myelin includes a fluorescent stilbenzene derivative. | 09-02-2010 |
20100316567 | ETHER AND ALKYL PHOSPHOLIPID COMPOUNDS FOR TREATING CANCER AND IMAGING AND DETECTION OF CANCER STEM CELLS - Methods and compositions utilizing ether and alkyl phospholipid ether analog compounds for treating cancer and imaging, monitoring, and detecting cancer stem cells in humans. | 12-16-2010 |
20110008252 | STABALISED 99MTC COMPOSITIONS - The present invention relates to stabilised | 01-13-2011 |
20110064660 | DEUTERATED ALKYL PHOSPHOLIPID COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - The invention generally relates to novel deuterated phospholipid compounds, compositions comprising these compounds, and their use in a variety of cancer therapy and diagnostic applications. | 03-17-2011 |
20110064661 | NON-RADIOACTIVE PHOSPHOLIPID COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - The present invention provides phospholipid ether and alkyl phospholipid compounds and their combinations with other cancer therapy agents. More specifically, the invention relates to the use of phospholipid ether compounds comprising a “cold” isotope of iodine, e.g. | 03-17-2011 |
20120039803 | PRETARGETING KIT, METHOD AND AGENTS USED THEREIN - Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an alkene or alkyne dienohile. | 02-16-2012 |
20120148492 | BISPHOSPHONIC ACID DERIVATIVE AND COMPOUND THEREOF LABELED WITH RADIOACTIVE METAL NUCLIDE - Disclosed is a radioactive bone diagnostic agent which gives a high ratio of radioactivity accumulation in bone to that in blood from an early stage after administration of the agent and allows capturing an image in a short time after administration. Also disclosed is a bisphosphonic acid derivative represented by the following chemical formula (II) or a salt thereof, wherein X represents —(CH | 06-14-2012 |
20120156133 | NON-RADIOACTIVE PHOSPHOLIPID COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - The present invention provides phospholipid ether and alkyl phospholipid compounds and their combinations with other cancer therapy agents. More specifically, the invention relates to the use of phospholipid ether compounds comprising a “cold” isotope of iodine, e.g. | 06-21-2012 |
20120328518 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS - This invention relates to novel compounds suitable for labelling by | 12-27-2012 |
20130064768 | LIPOPHILIC CATIONIC PROBE FOR PET-IMAGING - The present invention provides an imaging probe which comprises a lipophilic cation, a hydrophobic moiety and a PET nucleus. The present invention also provides a precursor molecule for the production of such an imaging probe and methods for using the probe for analysing mitochondrial membrane potential in a subject. | 03-14-2013 |
20130280165 | MICROSPHETRE COMPRISING A LANTHANIDE METAL COMPLES - The invention is directed to a method for preparing a microsphere comprising a lanthanide metal phosphate complex, a microsphere, a powder comprising a number of the microspheres, a suspension comprising the microsphere or the powder, the use of the microsphere, a method for detecting a tumour, and a therapeutic composition comprising the microsphere, the powder, or the suspension. | 10-24-2013 |
20130343991 | ETHER AND ALKYL PHOSPHOLIPID COMPOUNDS FOR TREATING CANCER AND IMAGING AND DETECTION OF CANCER - Methods and compositions utilizing ether and alkyl phospholipid ether analog compounds for treating cancer and imaging, monitoring, and detecting cancer stem cells in humans. | 12-26-2013 |
20140023587 | PHOSPHOLIPID ANALOGS AS DIAPEUTIC AGENTS AND METHODS THEREOF - The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers. | 01-23-2014 |
20140030187 | PHOSPHOLIPID ETHER ANALOGS AS AGENTS FOR DETECTING AND LOCATING CANCER, AND METHODS THEREOF - The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs. | 01-30-2014 |
20140079632 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR - The present invention relates to selective trypsine-like serine protease activity-based probes, in particular urokinase plasminogen activator-activity based probes, the use thereof and methods for detecting selective urokinase activity by making use of said probes. | 03-20-2014 |
20140199240 | ANTICANCER AGENT - The invention relates to a method for preparing a bisphosphonate covalently bonded to a nanostructure. This invention also relates to a bisphosphonate having incorporated therein a radioisotope selected from | 07-17-2014 |
20140241985 | Chelated PSMA Inhibitors - Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells. | 08-28-2014 |
20150030538 | PHOSPHOLIPID ETHER ANALOGS AS AGENTS FOR DETECTING AND LOCATING CANCER, AND METHODS THEREOF - The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs. | 01-29-2015 |
20150093330 | PHOSPHOLIPID ANALOGS AS DIAPEUTIC AGENTS AND METHODS THEREOF - The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers. | 04-02-2015 |
20150132222 | METHODS AND COMPOSITIONS FOR POSITRON EMISSION TOMOGRAPHY MYOCARDIAL PERFUSION IMAGING - This invention provides compounds and compositions useful as imaging tracers for positron emission tomography myocardial perfusion imaging (PET MPI). Compounds in accordance with embodiments of the invention will generally comprise three structural elements: i) a triphenylphosphonium moiety; ii) a chelating element; and iii) a hydrophobic element. The tracer compounds are preferably radiolabeled with | 05-14-2015 |
20150374857 | Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression - The inventive method relates to a method for the determination of susceptibility or diagnosis of autism or autism spectrum disorders. Diagnosis or determination of susceptibility determinations are predicated on quantitative analysis of endocannibinoid levels or endocannibinoid receptor expression. | 12-31-2015 |
20160158390 | Methods for Tumor Diagnosis and Therapy - The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule. | 06-09-2016 |
20160185805 | PROBE FOR IMAGING PARP-1 ACTIVITY - Provided are embodiments of a small molecule tracer for positron emission tomography (PET) imaging of the enzyme activity of PARP-1 that is responsible for DNA-damage sensing and critically involved in radiation therapy and some chemotherapy response mechanisms. These PARP-1 tracers are derivatives of nicotinamide adenine dinucleotide (NAD), which is the natural substrate for PARP-1. Provided are NAD derivatives that include a linker moiety to which may be attached a label moiety such as a PET detectable fluorine to generate a 6N-(triazo-PEG2- | 06-30-2016 |
20160193235 | Mitochondrially-Targeted Electrophilic Compounds and Methods of Use for the Treatment of Cancer | 07-07-2016 |
20180021461 | TARGETED RADIOTHERAPY CHELATES FOR IN SITU IMMUNE MODULATED CANCER VACCINATION | 01-25-2018 |
20180022768 | RADIOACTIVE PHOSPHOLIPID METAL CHELATES FOR CANCER IMAGING AND THERAPY | 01-25-2018 |